UPDATE: RedHill Biopharma CEO Tells Benzinga Its BEKINDA In IBS-D Indication, If Successful, Will Have 'Significant Pricing Elasticity,' Notes IBS Treatments Are Expensive, Says 'Fully reimbursed, we can do very well in that market'